International Stem Cell Corporation’s stem cell technology platform has been called one of the most important in modern medicine. The company owns the key patents for parthenogenetic stem cells (hpSCs), pluripotent stem cells derived from unfertilized oocytes (eggs) collected during in vitro fertilization.
Since hpSCs are not derived from human embryos, the ethical issues that plague the use of embryonic stem cells are not an issue. It’s a derivation method that also provides unique advantages when it comes to the problem of cell rejection by the patient, since hpSCs have only the mother’s DNA. Such a limited DNA set means that there is far less chance of rejection when such cells are used for therapy. As a result, a relatively few hpSC cell lines could be compatible for use with the vast majority of people on earth. And, unlike adult stem cells, hpSCs are pluripotent, able to be transformed into many types of cells, for use in many applications. Collectively, these differences represent an extraordinary competitive advantage.
ISCO recently announced that they have now successfully created the world’s first human clinical-grade stem cell lines that can be immune-matched to millions of individuals, initial lines that comply with strict government standards for medical application. These cells can now be used in clinical trials for the treatment of various diseases, and the fact that they are hpSC cells means that they will have a much smaller chance of being rejected by a given patient than other types of stem cells. Diseases currently being considered for investigation include Parkinson’s and other brain/nerve related diseases, liver diseases, and diabetes, as well as diseases of the eye.
The collective market for such diseases spans millions of people and billions of potential market dollars, and ISCO has now shown that hpSCs, with all of their advantages, are a producible and viable option for the world medical community.
For more information on ISCO and its stem cell technologies, visit www.internationalstemcell.com
Let us hear your thoughts below: